Literature DB >> 32764116

NADPH oxidase DUOX1 sustains TGF-β1 signalling and promotes lung fibrosis.

Ruy Andrade Louzada1, Raphaël Corre1, Rabii Ameziane El Hassani2, Lydia Meziani3, Madeleine Jaillet4, Aurélie Cazes5, Bruno Crestani4,6,7, Eric Deutsch3, Corinne Dupuy8.   

Abstract

Interstitial lung fibroblast activation coupled with extracellular matrix production is a pathological signature of pulmonary fibrosis, and is governed by transforming growth factor (TGF)-β1/Smad signalling. TGF-β1 and oxidative stress cooperate to drive fibrosis. Cells can produce reactive oxygen species through activation and/or induction of NADPH oxidases, such as dual oxidase (DUOX1/2). Since DUOX enzymes, as extracellular hydrogen peroxide (H2O2--)-generating systems, are involved in extracellular matrix formation and in wound healing in different experimental models, we hypothesised that DUOX-based NADPH oxidase plays a role in the pathophysiology of pulmonary fibrosis.Our in vivo data (idiopathic pulmonary fibrosis patients and mouse models of lung fibrosis) showed that the NADPH oxidase DUOX1 is induced in response to lung injury. DUOX1-deficient mice (DUOX1+/- and DUOX1-/-) had an attenuated fibrotic phenotype. In addition to being highly expressed at the epithelial surface of airways, DUOX1 appears to be well expressed in the fibroblastic foci of remodelled lungs. By using primary human and mouse lung fibroblasts, we showed that TGF-β1 upregulates DUOX1 and its maturation factor DUOXA1 and that DUOX1-derived H2O2 promoted the duration of TGF-β1-activated Smad3 phosphorylation by preventing phospho-Smad3 degradation. Analysis of the mechanism revealed that DUOX1 inhibited the interaction between phospho-Smad3 and the ubiquitin ligase NEDD4L, preventing NEDD4L-mediated ubiquitination of phospho-Smad3 and its targeting for degradation.These findings highlight a role for DUOX1-derived H2O2 in a positive feedback that amplifies the signalling output of the TGF-β1 pathway and identify DUOX1 as a new therapeutic target in pulmonary fibrosis.
Copyright ©ERS 2021.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 32764116     DOI: 10.1183/13993003.01949-2019

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  6 in total

1.  Profibrotic epithelial TGF-β1 signaling involves NOX4-mitochondria cross talk and redox-mediated activation of the tyrosine kinase FYN.

Authors:  Carmen Veith; Milena Hristova; Karamatullah Danyal; Aida Habibovic; Christopher M Dustin; John E McDonough; Bart M Vanaudenaerde; Michael Kreuter; Marc A Schneider; Nicolas Kahn; Frederik J van Schooten; Agnes W Boots; Albert van der Vliet
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2020-12-16       Impact factor: 5.464

Review 2.  DUOX1 in mammalian disease pathophysiology.

Authors:  Nuha Milad Ashtiwi; Demba Sarr; Balázs Rada
Journal:  J Mol Med (Berl)       Date:  2021-03-11       Impact factor: 4.599

3.  Effect of electro-acupuncture at ST 36 on maternal food restriction-induced lung phenotype in rat offspring.

Authors:  Qiujie Mou; Bo Ji; Guozhen Zhao; Yitian Liu; Reiko Sakurai; Yana Xie; Qin Zhang; Jian Dai; Yawen Lu; Yunpeng Ge; Tianyu Shi; Shuang Xu; Virender K Rehan
Journal:  Pediatr Pulmonol       Date:  2021-05-25

Review 4.  Aldehyde Dehydrogenase 2 as a Therapeutic Target in Oxidative Stress-Related Diseases: Post-Translational Modifications Deserve More Attention.

Authors:  Jie Gao; Yue Hao; Xiangshu Piao; Xianhong Gu
Journal:  Int J Mol Sci       Date:  2022-02-28       Impact factor: 5.923

5.  Setanaxib (GKT137831) Ameliorates Doxorubicin-Induced Cardiotoxicity by Inhibiting the NOX1/NOX4/Reactive Oxygen Species/MAPK Pathway.

Authors:  Hui Zheng; Nannan Xu; Zihao Zhang; Fen Wang; Jie Xiao; Xiaoping Ji
Journal:  Front Pharmacol       Date:  2022-04-04       Impact factor: 5.988

6.  NEDD4 attenuates phosgene-induced acute lung injury through the inhibition of Notch1 activation.

Authors:  Yiru Shao; Zhifeng Jiang; Daikun He; Jie Shen
Journal:  J Cell Mol Med       Date:  2022-03-31       Impact factor: 5.295

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.